- Bamlanivimab

A monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. In November 2020 the FDA issued an emergency use authorization for bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. A combination of two monoclonal antibodies, bamlanivimab and etesevimab, is administered together via intravenous infusion as a treatment for COVID-19.